Overview of TRP-related IDO-inhibitors currently under investigation... | Download Scientific Diagram
Epacadostat - an overview | ScienceDirect Topics
INCB24360 (epacadostat) – All About Drugs
Targeting the IDO1 pathway in cancer: from bench to bedside | Journal of Hematology & Oncology | Full Text
IDO to I DON'T – IDO1 Inhibitor Development News
aacrindoximod
Frontiers | Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers | Oncology
The State of IDO Inhibitor Combinations in the Treatment of Melanoma
Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry - MedChemComm (RSC Publishing) DOI:10.1039/C7MD00109F
Structural Basis of Selective Human Indoleamine‐2,3‐dioxygenase 1 (hIDO1) Inhibition - Kassab - 2021 - ChemMedChem - Wiley Online Library
IDO Is Still A Valid Pathway For NewLink Genetics (NASDAQ:LUMO) | Seeking Alpha
Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'. - Abstract - Europe PMC
Beyond PD-1 Immunotherapy in Malignant Melanoma | SpringerLink
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology | ACS Medicinal Chemistry Letters
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer -
Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab) | Business Wire
Epacadostat - Wikipedia
Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1 | Oncotarget
Indoximod - an overview | ScienceDirect Topics
Incyte climbs on combo data for IDO inhibitor epacadostat | Fierce Biotech
IDO Is Still A Valid Pathway For NewLink Genetics (NASDAQ:LUMO) | Seeking Alpha
Tryptophan Metabolism as a Pharmacological Target: Trends in Pharmacological Sciences
